Humanized Mouse and Rat Model - Global Strategic Business Report 2026: Capitalize on 9.7% CAGR to $231.6M by 2032 as Charles River, Biocytogen, Taconic and The Jackson Laboratory reshape drug R&D
B
BiotechNews.io5 min read
Improve R&D ROI with human-relevant models that reduce late-stage drug failures, accelerate development, and strengthen precision medicine outcomes.
Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Humanized Mouse and Rat Model - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.
Global Humanized Mouse and Rat Model Market to Reach US$231.6 Million by 2032
The global humanized mouse and rat model market was valued at US$121.4 million in 2025 and is projected to reach US$231.6 million by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. Market growth is being supported by rising demand for human-relevant preclinical research models, advances in gene-editing technologies, expanding immunotherapy pipelines, and increased investment in precision medicine.
Humanized mouse and rat models are increasingly important across drug discovery, oncology, immunology, infectious disease research, neuroscience, toxicology, and personalized medicine. Their ability to reproduce human-specific biological and immune responses can improve preclinical assessment of drug efficacy, safety, metabolism, and toxicity. These capabilities help pharmaceutical and biotechnology companies make better-informed development decisions and potentially reduce late-stage clinical failures.
Technology Trends Transforming Humanized Model Research
CRISPR-Cas9 and other gene-editing platforms are enabling researchers to create increasingly precise models that express human genes, proteins, receptors, and disease-associated mutations. These advances support research into cancer, autoimmune disorders, neurodegenerative diseases, metabolic conditions, and infectious diseases.
Humanized immune system models are gaining particular importance in the evaluation of immune checkpoint inhibitors, CAR T-cell therapies, monoclonal antibodies, vaccines, and antiviral treatments. Humanized liver models are also being adopted for drug metabolism, hepatotoxicity, hepatitis research, and pharmacokinetic studies. In parallel, stem cell technologies are supporting models containing human immune cells, neurons, glial cells, pancreatic cells, and other specialized cell types.
Multi-tissue humanized models represent another important development. By incorporating multiple human tissues or cellular systems, these models can support research into complex biological interactions, cancer metastasis, systemic immune responses, and therapies affecting multiple organs. Improved breeding, cryopreservation, transplantation, and animal husbandry practices are also strengthening model consistency, reproducibility, and scalability.
Market Growth Drivers
- Demand for more predictive preclinical models: Pharmaceutical and biotechnology companies are seeking research platforms that more accurately anticipate human responses to drug candidates.
- Expansion of immunotherapy: Growth in cancer immunotherapy and immune-mediated disease research is increasing demand for models capable of reproducing human immune function.
- Advances in gene editing: More precise genome engineering is accelerating the creation of disease-specific and target-specific mouse and rat models.
- Precision medicine investment: Patient-derived cells and tissues can support treatment selection and the evaluation of individualized therapeutic strategies.
- Infectious disease research: Continued research into HIV, hepatitis, respiratory viruses, and emerging pathogens is sustaining demand for humanized immune models.
- Regulatory and institutional support: Recognition of human-relevant preclinical evidence is encouraging investment by research institutions, contract research organizations, and life sciences companies.
Report Scope and Market Segmentation
The report analyzes the humanized mouse and rat model market by value in US dollars. Market coverage includes:
- Type: Humanized mouse models and humanized rat models.
- Application: Oncology, immunology and infectious diseases, neuroscience, hematopoiesis, and other applications.
- End Use: Academic and research institutions, pharmaceutical and biotechnology companies, and contract research organizations (CROs).
- Geography: United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Key Market Insights
- The humanized rat models segment is forecast to reach US$14.6 million by 2032, growing at a CAGR of 8.1%.
- The humanized mouse models segment is projected to expand at a CAGR of 9.8% during the analysis period.
- The U.S. humanized mouse and rat model market was valued at US$33.1 million in 2025.
- China is forecast to grow at a CAGR of 12.8% and reach US$47.3 million by 2032.
- The report also examines market trends in Japan, Canada, Germany, the wider European market, and Asia-Pacific.
Competitive Landscape
The global humanized mouse and rat model market includes established laboratory model providers, biotechnology companies, preclinical research specialists, and contract research organizations. Companies featured in the report include:
- Adam Rouilly Ltd.
- Altogen Labs
- Applied StemCell, Inc.
- Axenis S.A.S.
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Charles River Laboratories International, Inc.
- Crown Bioscience, Inc.
- Genoway S.A.
- Taconic Biosciences, Inc.
- The Jackson Laboratory
Strategic Value of the Report
- Independent annual market estimates and forecasts from 2025 through 2032.
- Detailed analysis of market size, growth rates, technologies, applications, end users, and geographic opportunities.
- Competitive intelligence covering leading market participants and their geographic presence.
- Assessment of emerging trends, growth drivers, constraints, and potential revenue opportunities.
- Company profiles and analysis of developments shaping the competitive environment.
- Complimentary report updates for one year.
Domain Expert Insights
The analysis incorporates perspectives from industry specialists, corporate decision-makers, researchers, and academic experts. The report tracks early market signals emerging from expert discussions, company activity, conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications, and other validated sources.
These insights connect technological and commercial developments with the market's strategic direction, highlighting the forces influencing adoption, competition, and investment. Competitive analysis extends beyond a single global market share figure, recognizing that supplier positions and market structures differ by geography. Where relevant, the report evaluates market share across major regions and aligns the level of analysis with local market dynamics.
Key Questions Addressed
- How will the global humanized mouse and rat model market evolve through 2032?
- Which technologies, applications, and end-use segments offer the strongest growth prospects?
- What factors are driving or constraining market expansion?
- How will regional market positions change during the forecast period?
- Which companies are shaping the competitive landscape?
- How are immunotherapy, gene editing, infectious disease research, and precision medicine influencing demand?
As life sciences organizations prioritize more predictive preclinical platforms, humanized mouse and rat models are expected to remain central to translational research, drug development, and personalized therapeutic strategies. Continued advances in genetic engineering, stem cell science, immune system modeling, and transplantation technologies are anticipated to broaden their applications and reinforce long-term market growth.
Key Attributes:
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value (USD) in 2025 | $121.4 Million |
| Forecasted Market Value (USD) by 2032 | $231.6 Million |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/ul3geg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
